Todd Smith

Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative non-opioid therapies for pain management, has appointed Todd Smith as an independent member of its Board of Directors. 

The appointment strengthens the company's leadership as it advances its pipeline of novel pain medicines designed to provide effective alternatives to opioid-based treatments.
Smith currently serves as Chief Executive Officer of Corium and brings more than 30 years of executive leadership, commercial strategy, and operational experience across the biotechnology and pharmaceutical industries. Throughout his career, he has led organizations through key stages of growth, including product development, commercialization, and corporate expansion.

His expertise spans strategic planning, business development, and the successful launch of innovative therapies in highly competitive healthcare markets. As a seasoned industry executive, Smith has built a strong track record of driving commercial success while supporting long-term business growth and value creation.

In his new role as an independent director, Smith will contribute his extensive industry knowledge to Latigo's Board as the company continues advancing its clinical programs focused on non-opioid pain treatments. His appointment reflects Latigo's commitment to strengthening its governance and leadership with experienced executives who can help guide the company's development strategy and future growth.

Latigo Biotherapeutics is dedicated to addressing the significant unmet need for safer pain management options by developing innovative therapies that reduce reliance on opioids. The addition of Smith to the Board is expected to support the company's mission as it progresses its clinical-stage portfolio toward potential commercialization.